Brief: Pharvaris Announces FDA Clinical Hold On PHA121 Clinical Trials In U.S.
22/08/2022 12:55
Aug 22 (Reuters) - Pharvaris NV PHVS.O :
* PHARVARIS ANNOUNCES FDA CLINICAL HOLD ON PHA121 CLINICAL
TRIALS
IN THE U.S.
* PHARVARIS NV- COMPANY PLANS TO PROVIDE ADDITIONAL UPDATES
FOLLOWING INTERACTIONS WITH FDA
* PHARVARIS NV- FDA INDICATED IT WILL PROVIDE A FORMAL
CLINICAL
HOLD LETTER TO PHARVARIS IN APPROXIMATELY 30 DAYS
Source text for Eikon: ID:nGNX5vS17C
Further company coverage: PHVS.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Pharvaris NV
See all newsSwitzerland's Pharvaris Q1 loss per share narrows
Brief: Pharvaris Announces Pricing Of $115 Million Underwritten Offering Of Ordinary Shares
U.S. STOCKS ON THE MOVE-Spirit AeroSystems, Boeing, Roblox
U.S. STOCKS ON THE MOVE-Microsoft, Wyndham Hotels & Resorts, Daktronics
U.S. STOCKS ON THE MOVE-Wendy's, Bristol Myers Squibb, Macy's